Compared to the 143B-EFHD1-cisplatin group, we observed a considerable decrease in tumor volume (Fig. 6B) and tumor weight (Fig. 6C) in the 143B-EFHD1-cisplatin-CATR group. The gene discussed is EFHD1; the disease is neoplasm.